Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Vs Tamsulosin for Stent Related Symptoms
NCT07307261Completed
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of mirabegron in ureteral stent-related complications (USRC) (3 arms). Primary endpoint: Treatment of Ureteral Stent Pain at 4 weeks. Started Oct 2024; status: completed.
02
Drugs
mirabegron
03
Conditions
ureteral stent-related complications (USRC)
Beyond the preview
Go deeper on NCT07307261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307261.